SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.
Basic Details
Issuer SSgA
Fund NameSPDR S&P Biotech ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:XBI
Inception Date1/31/2006
Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio
Phone+1-866-7872257
Fund Focus
Asset ClassEquity
BenchmarkS&P Biotech Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$3.95 billion
Average Daily Volume$3.76 million
Discount/Premium0.08%
ETF Expenses
Management Fee0.35%
Other Expenses0.00%
Total Expenses0.35%
Fee Waiver0.00%
Net Expenses0.35%
Administrator, Advisor and Custodian
AdministratorSSGA Funds Management, Inc.
AdvisorSSgA Funds Management, Inc.
CustodianState Street Bank and Trust Company
DistributorState Street Global Advisors Funds Distributors, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial
SPDR S&P Biotech ETF (NYSEARCA:XBI) Frequently Asked Questions
What is SPDR S&P Biotech ETF's stock symbol?
SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."
How often does SPDR S&P Biotech ETF pay dividends? What is the dividend yield for SPDR S&P Biotech ETF?
SPDR S&P Biotech ETF announced a -- dividend on Friday, September 20th. Stockholders of record on Monday, September 23rd will be given a dividend of $0.0032 per share on Wednesday, September 25th. This represents a dividend yield of 0.1%. The ex-dividend date is Friday, September 20th. View SPDR S&P Biotech ETF's Dividend History.
Has SPDR S&P Biotech ETF been receiving favorable news coverage?
Media coverage about XBI stock has trended somewhat negative on Monday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. SPDR S&P Biotech ETF earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned media stories about the exchange traded fund a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for SPDR S&P Biotech ETF.
What other stocks do shareholders of SPDR S&P Biotech ETF own?
Who are SPDR S&P Biotech ETF's key executives?
SPDR S&P Biotech ETF's management team includes the folowing people:
- James E. Ross, President, Trustee (Age 52)
- Peter A. Ambrosini, Chief Compliance Officer (Age 69)
- Michael P. Riley, Vice President (Age 44)
- Gary L. French, Treasurer (Age 64)
- John W. Clark, Assistant Treasurer (Age 46)
- Matthew W. Flaherty, Assistant Treasurer (Age 42)
- Chad C. Hallett, Assistant Treasurer of Street tracks series trust (Age 47)
- Mary Moran Zeven, Secretary (Age 52)
- Scott M. Zoltowski, Assistant Secretary (Age 44)
- Dave Kelly, Independent Trustee
Who are SPDR S&P Biotech ETF's major shareholders?
SPDR S&P Biotech ETF's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Morgan Stanley (19.34%), JPMorgan Chase & Co. (8.38%), Wells Fargo & Company MN (2.12%), Clal Insurance Enterprises Holdings Ltd (2.00%), Main Management ETF Advisors LLC (0.63%) and Bank of Nova Scotia (0.62%).
Which major investors are selling SPDR S&P Biotech ETF stock?
XBI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, JPMorgan Chase & Co., Wells Fargo & Company MN, Ardsley Advisory Partners LP, Reilly Financial Advisors LLC, Joseph P. Lucia & Associates LLC, PointState Capital LP and Migdal Insurance & Financial Holdings Ltd..
Which major investors are buying SPDR S&P Biotech ETF stock?
XBI stock was acquired by a variety of institutional investors in the last quarter, including HBK Investments L P, Capital Advisors Inc. OK, Parkside Investments LLC, Tower Research Capital LLC TRC, Deltec Asset Management LLC, Nuveen Asset Management LLC, Foothills Asset Management Ltd. and MML Investors Services LLC.
How do I buy shares of SPDR S&P Biotech ETF?
Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is SPDR S&P Biotech ETF's stock price today?
One share of XBI stock can currently be purchased for approximately $82.71.
How big of a company is SPDR S&P Biotech ETF?
What is SPDR S&P Biotech ETF's official website?
How can I contact SPDR S&P Biotech ETF?
SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.
MarketBeat Community Rating for SPDR S&P Biotech ETF (NYSEARCA XBI)
MarketBeat's community ratings are surveys of what our community members think about SPDR S&P Biotech ETF and other stocks. Vote "Outperform" if you believe XBI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBI will underperform the S&P 500 over the long term. You may vote once every thirty days.
